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Electrophysiologic Changes following Treatment with Organophosphorus-Induced Delayed 
Neuropathy-Producing Agents in the Adult Hen. ROBERTSON. D. G.. SCHWAB, B. W.. SILLS, 
R.D.,RICHARDSON,R.J.,ANDANDERSON,R.J. (1987). Touicol..4ppl. Pharmacol. 87,420- 
429. Although clinical, pathological, and biochemical effects of organophosphorus-induced de- 
layed neuropathy (OPIDN) have been intensively investigated in the adult hen, detailed electro- 
physiological studies are lacking. Adult white leghorn hens were treated with a single oral dose 
of either 30 mg/kg tri-2-cresyl phosphate (TOCP), 750 mg/kg TOCP. 4 mg/kg di-n-butyl-2,2- 
dichlorovinyl phosphate (DBCV). or 30 mg/kg di-n-butyl-2,2-dichlorovinyl phosphinate 
(DBCV-P). The 750 mg/kg TOCP and DBCV, but not the 30 mg/kg TOCP and DBCV-P. 
treatments resulted in clinical signs of OPIDN and mild to marked damage of the tibia1 nerve 
2 1 days after dose. Twenty-four hr lymphocyte neurotoxic esterase (NTE) inhibition was used as 
an index ofbrain NTE inhibition for the various organophosphorus compound (OP) treatment. 
Twenty-four hr lymphocyte NTE inhibition for 30 mg/kg TOCP. 750 mg/kg TOCP, DBCV. 
and DBCV-P was 54.1, 87.1, 84.8. and 68.3%. respectively. Twenty-one days after dose, the 
TOCP-treated hens exhibited some abnormalities in conduction velocity and action potential 
duration in the tibia1 or sciatic nerves. No abnormalities were observed in action potential pa- 
rameters of either the DBCV or DBCV-P treatments. Neurotoxic OP (TOCP and DBCV) treat- 
ment resulted in decreased refractoriness in the tibia1 nerve, increased refractoriness in the sciatic 
nerve, and elevated strength duration threshold for both nerves. These changes were not present 
in nerves from DBCV-P (a non-neurotoxic NTE inhibitor)-treated hens. These results suggest 
that refractory period and strength duration abnormalities in peripheral nerve correlate well 
with the production of OPIDN and are evident without coincident clinical signs or 
histopathology. &I 1987 Academic PRSS, Inc. 
Organophosphorus-induced delayed neurop- son, 1975; Davis and Richardson, 1980: 
athy (OPIDN) is a well-characterized clinical Abou-Donia, 198 1; Davis rt al., 1985). The 
syndrome that has been under investigation capacity of OPs to produce OPIDN correlates 
for over 50 years. This syndrome is best de- with their ability to inhibit neurotoxic ester- 
fined as a sensorimotor axonopathy which ase (NTE), although there are compounds 
particularly affects long, large diameter axons that inhibit NTE that are not neurotoxic. 
in a distal-to-proximal fashion (dying-back Johnson ( 1974) has suggested that the neces- 
neuropathy). Structure-activity relationships sary step for the production of OPIDN is the 
of organophosphorus compounds (OPs) pro- cleavage of a phosphoryl ester bond to leave 
ducing OPIDN have been well documented a charged monosubstituted phosphoric acid 
and are the subject of several reviews (John- group on the enzyme, a process called aging. 
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Although the relationship between NTE or- 
ganophosphorylation and OPIDN produc- 
tion has been rigorously investigated, a mech- 
anistic link between these two actions has re- 
mained elusive. 
One problem with mechanistic investiga- 
tions of OP neuropathy is that typically hen 
brain is used to assess NTE inhibition 24 hr 
after dosing, even though clinical and histo- 
pathological signs of OPIDN do not usually 
become apparent for 8-2 1 days. Recovery of 
NTE activity after inhibition by OPs is fairly 
rapid with a ti for recovery ranging from 4 
to 7 days (Johnson, 1975). Therefore, NTE 
activity approaches control values at the on- 
set of peripheral neuropathy. Most previous 
studies of NTE and OPIDN have used paired 
groups of animals: one for brain NTE activity 
measurements and the other for measure- 
ment of some aspect of OPIDN. However, 
because of the individual variation in the de- 
gree of inhibition of NTE and neuropathic 
susceptibility following a given dose of OP, 
correlations between these two effects have 
been further confounded. Our work (Dudek 
and Richardson, 1980,1982; Richardson and 
Dudek, 1983) has demonstrated significant 
NTE activity in hen peripheral lymphocytes, 
and we have shown that brain and lympho- 
cyte NTE activities are well correlated within 
24 hr after single doses of neurotoxic OPs 
(Schwab and Richardson, 1986). Therefore 
by using lymphocytes to measure NTE, as- 
sessment of OPIDN and NTE can be ob- 
tained from the same animal, eliminating 
one key source of variation. 
Electrophysiological assessment of periph- 
eral nerves after treatment with OP com- 
pounds has primarily been studied in the cat 
(Lowndes et al., 1974; Baker and Lowndes, 
1980; Baker et al., 1980), the rat (Averbook 
and Anderson, 1983; Anderson, 1983; An- 
derson and Dunham, 1985), and to a limited 
extent in the hen (Durham and Ecobichon, 
1984). These studies focused largely on mea- 
surements of conduction velocity, which is 
largely unchanged following OP administra- 
tion. Occasionally other functional measure- 
ments (relative refractory period and sensory 
afferent activity) have been made, but no pre- 
vious studies have systematically examined 
the effect of OPs on a variety of electrophysio- 
logic characteristics in the hen. The purpose 
of this study was to examine a variety of elec- 
trophysiological parameters in the hen at a 
time when the animal was expressing overt 
clinical signs of OPIDN. Peripheral lympho- 
cyte NTE activity was assessed 24 hr after 
dosing. Tri-2-cresyl phosphate (TOCP), 
which requires metabolic activation to be- 
come neurotoxic, and di-n-butyl-2,2-dichlor- 
ovinyl phosphate (DBCV) were chosen as 
model OPIDN compounds. In addition, the 
phosphinate analog of DBCV, di-n-butyl-2,2- 
dichlorovinyl phosphinate (DBCV-P, a non- 
neurotoxic NTE inhibitor), was used to con- 
trol for the effects of NTE inhibition on pe- 
ripheral nerve electrical activity. 
METHODS 
Animals and housing. Adult (> 1 year old. 1.4-2.2 kg) 
white leghorn hens (Omega Chicks, Haslett, MI) were 
maintained in groups of three to four in stainless-steel 
cages (0.8 X 0.8 X 0.9 m) with wire-mesh floors in a temp- 
erature-controlled (2 I-23°C) room with a 12-hr light/ 12- 
hr dark cycle. Except for predose fasting. food (Purina 
Layena Mash) and tap water were available ad libitum. 
Dosing. AI1 OPs were dissolved in Mazola corn oil and 
administered as a single dose in a volume of 2 ml/kg by 
oral cannula directly into the crop of hens fasted for 24 
hr. Two groups ofhens received 30 and 750 mg/kgTOCP 
(practical grade, Sigma Chemical Co., St. Louis, MO), 
respectively. Additional groups of hens were dosed with 
either 4 mg/kg DBCV or 30 mg/kg DBCV-P, while the 
control group received vehicle alone. DBCV and DBCV- 
P were custom-synthesized by Ash Stevens Inc. (Detroit, 
MI) and the purity of these compounds was determined 
to be ‘99% by gas chromatography-mass spectrometry. 
A minimum of seven birds was dosed in each group. The 
higher TOCP dose and the DBCV dose were chosen on 
the basis of preliminary studies which demonstrated 
marked NTE inhibition for both treatments as well as the 
production of clinical signs of OPIDN within 21 days. 
The lower dose of TOCP produced approximately 50% 
NTE inhibition and no clinical signs in preliminary stud- 
ies. The dose of DBCV-P was selected in preliminary 
studies to be equipotent with the neurotoxic DBCV for 
NTE inhibition. Hens were weighed prior to and 2 1 days 
after dose and were observed daily for clinical signs of 
toxicity. Clinical evidence of OPIDN was graded as fol- 
lows: 0 = no signs, 1 = gait abnormalities, 2 = animal 
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observed resting on haunches but the ability to stand still 
remains, and 3 = complete prostration. 
NTE USS~J’X Blood (7- 10 ml) was taken from the wing 
vein using a heparinized syringe 24 hr after dosing. Lym- 
phocytes were isolated and NTE assays were conducted 
as described by Schwab and Richardson (1986). Protein 
was determined using a Bio-Rad protein assay kit (Bio- 
Rad Laboratories, Richmond, CA) using bovine serum 
albumin, fraction V (Sigma Chemical, St. Louis, MO) as 
a standard. Specific activity was then calculated as nmol 
substrate hydrolyzed mini’ mg protein-‘. 
Lymphocyte NTE activity can be used as an index of 
brain NTE inhibition for TOCP and DBCV (Schwab and 
Richardson, 1986). However, a correlation between lym- 
phocyte and brain NTE inhibition after DBCV-P admin- 
istration was not available. Therefore, prior to these stud- 
ies, a dose-response curve for DBCV-P was generated for 
both lymphocyte and brain NTE (24 hr after dosing) and 
the correlation was established using the method de- 
scribed by Schwab and Richardson (1986). 
E/ectrophysiolog,v. Birds were examined for electro- 
physiological changes 2 1 days after dosing. Surgical and 
electrophysiological methods have been described else- 
where (Robertson and Anderson, 1986). Briefly. hens 
were anesthetized with 60 mg/kg a-chlorolose (Fisher 
Scientific, Detroit, MI) which was injected into a wing 
vein. Both the tibia1 and sciatic nerves were surgically 
isolated. A short segment (2-4 mm) of the distal end of 
the tibial nerve was removed and placed in 6% phosphate 
(Sorenson’s, pH 7.4)-buffered glutaraldehyde for fixation 
and later histology. During recording, nerves were im- 
mersed in mineral oil maintained at 39.5 f  O.l”C by 
means of a heat lamp coupled to a Thermistemp temper- 
ature controller (Yellow Springs Instruments. Yellow 
Springs, OH). The activities from both the tibia1 and the 
sciatic nerves were recorded in a similar manner. Nerves 
were positioned on pairs of bipolar stimulating and re- 
cording electrodes fixed in a plastic holder maintaining 
the interelectrode distance at 30 mm. A computer-as- 
sisted method for recording and analyzing the nerve 
compound action potential has been described pre- 
viously (Anderson et al., 198 1). Briefly, 50 supramaxi- 
ma1 stimuli of 0.02-msec duration were presented at 15- 
set intervals. The following characteristics were obtained 
for each compound action potential: (1) onset conduc- 
tion velocity, (2) peak conduction velocity, (3) action po- 
tential duration. and (4) action potential amplitude. Af- 
ter the characteristics of the action potential were ob- 
tained, the relative refractory period for the nerve was 
measured. This was done using twin pulse stimulation 
at interstimulus intervals from 1 to 8 msec. The relative 
refractory period was calculated using a modification of 
the method of Roberts and Trollope (1979) and con- 
verted to linear form using the method of Anderson 
(1983). 
Strength-duration curves were obtained by measuring 
the voltage required to elicit threshold depolarization of 
the nerve at stimulus durations from 10 to 1000 psec. 
Chronaxie and rheobase measurements were obtained 
from these curves. In addition, the inflexion region of the 
curve (40-100 psec) was converted to a linear form by 
logarithmic transformation of both the ordinate and ab- 
scissa to facilitate comparison of the treatment groups, 
Histology. The tibia1 nerve segments removed before 
recording were allowed to fix for 3 hr, washed in Soren- 
son’s buffer (pH 7.4). and stored at 4°C in fresh buffer. 
Nerves were eventually dehydrated through a graded se- 
ries of ethanol solutions and embedded in Spurr resin 
(Polysciences, Wanington, PA), placed in flat molds, and 
hardened in an oven at 60°C. Sections ( 1 Frn) were cut 
on an ultramicrotome, stained with toluidine blue. and 
observed for histological changes by light microscopy. 
Statistics. Analysis of variance with the Newman- 
Keuls method of multiple comparisons was used to de- 
termine statistical difference between mean compound 
action potential data with p < 0.05 set as the criterion of 
significance. The linear data (relative refractory period 
and strength-duration curves) were compared using 
analysis of covariance to determine significant differ- 
ences in both slope and intercept of calculated lines. All 
data are expressed as means f  standard error. 
RESULTS 
Both the 750 mg/kg TOCP- and DBCV- 
treated birds demonstrated clinical signs of 
toxicity as early as 12 days after dosing. These 
signs included gait abnormalities which be- 
came progressively more severe and in some 
cases led to complete ataxia. The 750 mg/kg 
TOCP-dosed birds appeared to be affected to 
a greater extent than the DBCV-treated birds. 
DBCV birds, although exhibiting obvious 
gait impairment, nevertheless appeared to be 
in good general health and did not lose as 
much weight as the TOCP-treated birds. The 
lower dose of TOCP did not elicit any sign 
of gait abnormalities. However, the animals 
were noticeably unkempt and lost weight. No 
clinical signs of toxicity were observed in the 
DBCV-P-treated group. A summary of clini- 
cal signs and weight changes during the time- 
course of the experiment is presented in Ta- 
ble 1. 
Although no animals died during the 
study, a number of treated birds did not sur- 
vive the anesthesia or surgery. This resulted 
in different numbers of birds for the various 
experiments. Except where noted, at least five 
birds were tested for each experiment. 
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TABLE 1 
INDICES OF TOXICITY TO HENS EXPOSED TO VARIOUS OP TREATMENTS 
Clinical signs’ 
@‘u) Lymphocyte NTE’ 
Weight change” inhibition 
Treatment (IV)~ (8) 0 1 2 3 (%) 
Control ( 12) +88i 38 100 0 0 0 - 
30 mg/kg TOCP (7) -12oi 48 100 0 0 0 54.1 f  8.3 
750 mg/kg TOCP (8) -348k 71 0 25 37.5 37.5 87. I i- 2.0 
4 mg/kg DBCV (7) -62+ 113 0 71.5 28.5 0 84.8 f  2.8 
30 mg/kg DBCV-P (8) +104+ 32 100 0 0 0 68.3 zk 6.9 
’ Average weight of animals at sacrifice - average predose weight. 
’ Clinical signs of neurotoxicity at sacrifice (W of animals in group): 0 = no signs: 1 = gait abnormalities; 2 = animal 
rests on haunches but can stand: and 3 = completely ataxic. 
’ ( 1 - Mean NTE activity oftreated group/mean NTE activity of control animals) X 100. 
’ Number of animals in each group. 
The results of the study investigating the 
correlation of hen brain and lymphocyte 
NTE inhibition by DBCV-P is presented in 
Fig. 1. The correlation was statistically sig- 
nificant (r2 = 0.57. p < 0.01) and the higher 
end of the dose-response curve (>20 mg/kg) 
demonstrated particularly good agreement. 
The results of the 24-hr lymphocyte NTE 
assays in the various treatment groups are 
i A . 
I - I 
FIG. 1. Relationship between inhibition of lymphocyte 
NTE and inhibition of brain NTE in hens treated with 
either 2 (A). 5 (O), 20 (Cl). or 30 (a) m&kg DBCV-P 24 hr 
after dosing. Each point represents an individual animal. 
The coefficient of determination (r’) for the line is 0.57 
(p < 0.0 1, t test). Control lymphocyte NTE activity was 
5.96 t_ 1.83 nmol phenyl valerate hydrolyzed/min X mg 
protein (n = 8). Control brain NTE activity was 24.37 
+ 3.20 nmol phenyl valerate hydrolyzed/min X mg pro- 
tein ()I = 8). 
presented in Table 1. Only four hens were as- 
sayed for the DBCV assay. All birds in the 
high TOCP and DBCV groups had lympho- 
cyte NTE inhibitions above 70% and all dis- 
played OPIDN. Interestingly, two birds in the 
low TOCP group also had lymphocyte NTE 
inhibition above 70% (7 1 and 82%) yet nei- 
ther displayed any motor impairment. Al- 
though preliminary studies indicated that the 
30 mg/kg dose of DBCV-P should have in- 
hibited lymphocyte NTE by greater than 
80%, the mean value was only 68%. Three out 
of the seven treated animals had lymphocyte 
NTE inhibitions greater than 70%. 
Table 2 presents the compound action po- 
tential parameter measurements obtained for 
the various treatment regimens for both the 
tibia1 and sciatic nerves. Both TOCP treat- 
ments resulted in significant changes in ac- 
tion potential parameters, whereas neither 
DBCV or DBCV-P treatment produced any 
significant difference in the action potential. 
Action potential duration was significantly 
increased in the tibia1 nerve, and onset con- 
duction velocity was significantly decreased 
in the sciatic nerve with TOCP. 
The relative refractory periods of both the 
tibia1 and sciatic nerves were significantly al- 
tered by all three neurotoxic OP treatments. 
The sciatic nerve refractory period was 
shifted to the right by neurotoxic OP treat- 
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TABLE 2 




30 mg/kg TOCP 
750 mg/kg TOCP 
4 mg/kg DBCV 
30 mg/kg DBCV-P 
Sciatic nerve 
Control 
30 mg/kg TOCP 
750 mg/kg TOCP 
4 mg/kg DBCV 





41.3 f  2.8 
35.3 rt 1.9 
39.2 f  2.7 
41.8 ? 2.5 
40.1 2 2.8 
60.5 f  3.0 
48.3 14. I u 
43.1 2 1.9” 
57.6 f  1.9 





26.5 f  1.6 0.67 f  0. I2 
32.0 -I- 1.0 0.30 f  0.09 
21.7 f  1.5 0.24 f  0.05 
28.3 2 1.3 0.66 f  0.13 
27.6 t 1.9 1.06 zk 0.29 
32.0 k 2.2 1.10?0.17 
27.0 f  1.3 1.04 f  0.35 
25.6 +- 1.6 0.78?00.16 
30.6 f  1.4 1.30 * 0.20 
31.5 f  1.9 1.45 f  0.36 
Duration Chronaxie 
(msec) (msec) 
1.08 k 0.11 0.019+0.001 
1.69 f  0.30” 0.020 f  0.00 1 
1.16 f  0.23“ 0.023 f  0.002 
0.96 f  0.08 0.026 + 0.00 1’ 
1.07 f  0.15 0.024 f  0.00 1 
1.21 + 0.06 0.024 f  0.001 
1.68 -+ 0.05 0.027 f  0.00 1 
1.30 f  0.07 0.028 f  0.002 
1.17*0.10 0.035 f  0.001 u 
1.05 f  0.04 0.038 f  0.003” 
Rheobase 
(mv) 
1.70 & 0.06 
1.84 & 0.08 
1.97 2 0. I I 
1.91 kO.10 
1.6OkO.l 1 
1.80 + 0.03 
1.90 + 0.07 
1.97 + 0.08 
2.01 +0.1 I 
1.55 + 0.04” 
ment (Fig. 2a) while the tibia1 nerve was 
shifted to the left (Fig. 2b). In addition, there 
was no evidence of supranormal response ob- 
served in the oscilloscope traces of either 
nerve. There was a trend toward a decreased 
slope in the relative refractory period of the 
sciatic nerve from OP-treated birds. How- 
ever, this effect was not statistically signifi- 
cant. No change in slope was observed for the 
tibia1 nerve. DBCV-P did not significantly al- 
ter the relative refractory period for either 
nerve. 
The strength-duration curves for both 
nerves showed an increase in threshold excit- 
ability of the nerves following neurotoxic OP 
treatment (Fig. 3). This increase manifested 
itself as a parallel upward shift in the 
strength-duration curve. The shift due to 
TOCP treatment was dose dependent in both 
nerves. DBCV treatment was more effective 
in inducing these changes than was either 
dose of TOCP. No change was observed in 
animals treated with DBCV-P. Chronaxie 
and rheobase calculations are presented in 
Ic 750 mglhg TOCP lb &30 mglhg TOCP 
1 2 3 4 ii 6 1 2 3 4 5 6 
TIME (msec) TIME (msec) 
FIG. 2. Log-linear representations of the relative refractory period for sciatic (a) and tibia1 (b) nerves 
after various OP treatments. Refractory period shifts were statistically significant (analysis of covariance, 
p < 0.05) for all neurotoxic OP treatments (TOCP and DBCV) but not for DBCV-P. 
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FIG. 3. Log-log representation of the inflection region (40-100 psec) of strength-duration curves from 
sciatic (a) and tibia1 (b) nerves of hens after various OP treatments. The strength duration threshold was 
significantly elevated (analysis of covariance, p < 0.05) for all neurotoxic OP treatments but not for 
DBCV-P. 
Table 2. OP treatment resulted in increases of 
both chronaxie and rheobase measurements. 
However, the only statistically significant 
change noted in the tibia1 nerve was a slight 
increase in chronaxie after DBCV treatment. 
In the sciatic nerve DBCV treatment resulted 
in a significant increase in chronaxie. In addi- 
tion the chronaxie of DBCV-P-treated hens 
was significantly elevated while the rheobase 
was significantly decreased. 
Microscopic investigation of tibia1 nerves 
revealed evidence of axonal damage only in 
the DBCV and 750 mg/kg TOCP groups, 
There was wide variation in individual ani- 
mal responses within these two groups. 
TOCP treatment resulted in various patho- 
logical sequelae including swollen axons. 
dark staining axoplasm, disrupted myelin, 
phagocyte infiltration, and complete axonal 
degeneration (Fig. 4b). Occasionally, phago- 
cytes were observed containing axonal debris. 
These effects were also noted in tibial nerves 
from DBCV-treated birds; however, axonal 
damage was not as extensive as that noted 
with TOCP treatment. Control specimens 
demonstrated mild myelin disruption (Fig. 
4a). However, no other evidence of abnormal 
morphology was present. 
DISCUSSION 
Doses of neurotoxic OPs sufficient to cause 
OPIDN within 21 days also caused pro- 
nounced changes in two electrophysiological 
parameters, the relative refractory period, 
and the strength-duration curve. These 
changes were not related to NTE inhibition 
alone, since DBCV-P (a nonageable and 
therefore nonneurotoxic NTE inhibitor) did 
not produce any of the changes seen after ad- 
ministration of the neurotoxic OPs. In addi- 
tion, the neurotoxic OPs induced electro- 
physiologic changes in animals given a dose 
of TOCP that did not produce any clinical or 
histopathological signs of OPIDN. 
The neurotoxic OPs had a pronounced 
effect on the relative refractory period. Sciatic 
nerves became more refractory, indicating 
that their ability to carry high frequency im- 
pulses was impaired. Treatment with DBCV- 
P (a nonaging NTE inhibitor) had no effect 
on this measurement, suggesting that the ob- 
served disruption of nerve impulse conduc- 
tion correlates with the ability of an OP to 
age. It is important to note that the low dose 
of TOCP, producing only 54% lymphocyte 
NTE inhibition and no clinical signs of toxic- 
ity, was just as effective at altering the relative 
refractory period as the higher TOCP and 
DBCV treatments. The refractory period of 
the tibia1 nerve was shifted to the left suggest- 
ing that the nerve actually became less refrac- 
tory after OP treatment. Although there are 
other examples of compounds that shift the 
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FIG. 4. Micrographs of 1-urn tibia1 nerve cross sections. (a) Control nerve showing artifactual myelin 
disruption (small arrows) and the presence of a blood vessel (large arrow). (b) Nerve from hen treated with 
750 mg/kg TOCP. Note the grossly swollen axon (s), numerous axons with darkly staining axoplasm (open 
arrow heads), phagocytes (p), and totally degenerated axons (solid arrow heads) which may or may not be 
contained within phagocytic cells. Toluidine blue stain, 800X original magnification. 
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relative refractory period to the left (Aver- 
book and Anderson, 1983) it is difficult to 
reconcile the effect of the neurotoxic OPs 
which shift the refractory period of the sciatic 
nerve to the right and the tibia1 nerve to the 
left. It should be noted that activity from the 
tibia1 nerve was recorded more distally than 
from the sciatic nerve. Since all measure- 
ments were made at 21 days after treatment 
and these OPs are known to produce a pro- 
gressive distal-to-proximal neuropathy, the 
condition of the more distal tibia1 nerve 
would not be expected to be at the same state 
of OPIDN as the more proximal sciatic nerve. 
The other electrophysiological parameter 
that was significantly affected by OP treat- 
ment was the strength-duration curve. Clini- 
cal neuroscientists have used this technique 
for evaluating a number of conditions includ- 
ing diabetic-, uremic, and alcohol-induced 
peripheral neuropathies (Friedli and Meyer, 
1984). However, this measurement has sel- 
dom been used in studies of organophospho- 
rus compounds. Neurotoxic OP treatment 
resulted in significant changes in both tibia1 
and sciatic nerves. These changes, as with the 
refractory period abnormalities, were related 
to those compounds which produce NTE in- 
hibition and also age. Observed elevations in 
the strength-duration curves suggest that 
neurotoxic OP treatment alters axonal mem- 
brane properties, resulting in elevated thresh- 
olds of peripheral nerves. An important ob- 
servation was that this effect occurred in the 
low dose TOCP group which showed no clini- 
cal evidence of OPIDN. The degree of thresh- 
old elevation following TOCP appeared to be 
dose related. However, in individual animals, 
the increase in the strength-duration curves 
did not correlate well with lymphocyte NTE 
inhibition. Along with the elevation of 
strength-duration curves there was also an 
increased chronaxie noted for all DBCV- 
treated tibia1 and sciatic nerves. Chronaxie is 
an index of nerve responsiveness calculated 
from the strength-duration curve and it per- 
mits comparison between treatment groups. 
The increase in chronaxie represents an in- 
creased threshold for nerve conduction in the 
OP-treated nerves. (It should be noted that 
the increased chronaxie noted with DBCV-P 
in the sciatic nerve was the result of a signifi- 
cant decrease in the rheobase.) 
Both TOCP-treated groups displayed sig- 
nificant action potential disruption in both 
the tibia1 and sciatic nerves (Table 2). These 
abnormalities were characterized by de- 
creased onset conduction velocity in the sci- 
atic nerve and increased action potential du- 
ration in the tibia1 nerve. Despite the pro- 
nounced effects of TOCP on both sciatic and 
tibia1 action potential, DBCV had no effect 
on any action potential parameter. This sug- 
gests that the changes observed with TOCP 
were not related to NTE inhibition or the 
production of OPIDN. These electrophysio- 
logic results, along with the weight loss and 
unkempt appearance observed in the TOCP- 
treated hens, suggested that the action poten- 
tial abnormalities following TOCP treatment 
may be secondary to other toxic actions of the 
compound. Durham and Ecobichon (1984) 
reported no change in sciatic nerve conduc- 
tion velocity in hens given single oral doses of 
500 mg/kg TOCP and sacrificed at 7, 14.28, 
42. and 56 days after treatment. 
Perhaps the difference between our study 
and that of Durham and Ecobichon was the 
purity of the TOCP. Practical grade TOCP 
frequently has various impurities which may 
vary from batch to batch. These impurities 
may be responsible for variations in toxicity 
(Gary Sprague, Personal communication). 
The results obtained using low potency OPs 
in experimental OPIDN studies should there- 
fore be interpreted with caution. 
Lymphocyte NTE inhibition proved to be 
a reliable indicator of brain NTE inhibition. 
In addition. the correlation of DBCV-P-in- 
duced inhibition of brain with inhibition of 
lymphocyte NTE suggests that DBCV and 
DBCV-P make an excellent pair of structural 
analogs for studying the relationship of NTE 
inhibition and the production of OPIDN. It 
has been recognized for some time that a nec- 
essary fraction of NTE must be inhibited be- 
fore clinical signs of OPIDN are manifest. 
This fraction has generally been accepted 
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as approximately 70% (Johnson, 1975). 
Whether this implies an actual threshold or 
not is currently the subject of some debate 
(Schwab and Richardson, 1986). 
The morphology of the tibia1 nerve demon- 
strated conclusive evidence of OPIDN. The 
milder lesions noted in nerves from DBCV- 
treated hens as compared to 750 mg/kg 
TOCP-treated hens correlated with the less 
severe clinical signs noted in the former 
group. The structural damage described was 
typical of that noted for OPIDN, as recently 
described for the fibular nerve of hens ex- 
posed to DFP (disopropyl fluorophosphate) 
(Ehrich et al., 1985). Since electrophysiologic 
assessment precluded the use of perfusion or 
in situ fixation techniques, it was not unex- 
pected that some fixation artifact would be 
present. Fixation artifact was most evident in 
myelin where sloughing and separation were 
frequently seen (Fig. 4a). 
Perhaps the most important finding of this 
study was the observed electrophysiological 
changes at a dose of TOCP that did not pro- 
duce any clinical or histopathological sign of 
OPIDN. These observations question the va- 
lidity of the so-called threshold (i.e., 70% 
NTE inhibition) necessary for the production 
of OPIDN. However, since the relationship 
of the observed electrophysiological changes 
to the production of OPIDN is not yet 
known, the idea of a threshold cannot be 
eliminated. The prevailing hypothesis con- 
cerning the mechanism of OPIDN involves 
the phosphorylation of NTE with subsequent 
aging of the OP-enzyme complex. The corre- 
lation of the electrophysiological changes 
with aging suggests that the observed axonal 
conduction deficits are a result of the aging 
of the OP-enzyme complex. If this is true, it 
establishes an important link between NTE 
and clinical OPIDN. 
In conclusion, our results show that electri- 
cal changes occur in peripheral nerves in re- 
sponse to neuropathogenic OP treatment. OP 
treatment results in alterations in both rela- 
tive refractory period and strength-duration 
curves. In general, these changes are charac- 
terized by increased refractoriness in the sci- 
atic nerve and decreased excitability in both 
the sciatic and tibia1 nerves. These abnormal- 
ities appear to require both NTE inhibition 
and aging, rather than inhibition alone. Fi- 
nally, these changes occurred with TOCP at 
a dose producing no clinical or histopatho- 
logical evidence of OPIDN. Future work will 
deal with the time-course of these electro- 
physiological deficits, and the effects of pre- 
treatment with nonaging OPs (i.e., DBCV-P) 
used to block the production of OPIDN. 
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